

Legacy for decades 24/7 Service and Support

Through moments of calm and crisis, the INOmax Total Care® offering has been there



INOmax™ (inhaled nitric oxide), in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and late pre-term (≥ 34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

Consult the product monograph at <https://www.mallinckrodt.ca/wp-content/uploads/2019/02/INOMAX-PM-Oct2017.pdf> for important information about:

- Contraindication in patients whose systemic oxygenation is wholly dependent on extra-pulmonary right-to-left shunting
- The most serious warnings and precautions regarding left-to-right shunting
- Other relevant warnings and precautions regarding inadequate clinical response, rebound pulmonary hypertension, methemoglobinemia, NO₂ formation, left ventricular dysfunction, and hemostasis interactions
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

The product monograph is also available by calling us at 1-877-566-9466.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2025 Mallinckrodt. CA-2500007 01/25



Mallinckrodt
Pharmaceuticals